Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (28)	2/27/2002 1:39:20 AM
From: Miljenko Zuanic	Respond to of 117

Tuesday February 26, 12:30 pm Eastern Time Press Release SOURCE: Alkermes, Inc. Poster Titled 'Maintenance of Efficacy Without Compromising Safety When Switching From Oral Risperidone to Risperdal Consta', Posted On Alkermes' Website CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 26, 2002--Alkermes, Inc., (NASDAQ: ALKS - news) today announced that it added a poster to its website entitled ``Maintenance of Efficacy Without Compromising Safety When Switching from Oral Risperidone to Risperdal Consta(TM), a Long-acting Injection Formulation of Risperidone.'' The poster was presented today, Tuesday, February 26, 2002 at 12:30pm ET at the Winter Workshop on Schizophrenia in Davos, Switzerland. This poster demonstrates the maintenance of efficacy without compromising safety when switching from Risperdal® (risperidone) tablets to Risperdal Consta. The poster is available on the Alkermes website at www.alkermes.com/news. A new drug application (NDA) for Risperdal Consta was submitted to the U.S. Food and Drug Administration on August 31, 2001 by Johnson & Johnson Pharmaceutical Research & Development, which conducted the clinical-development program. If approved by the FDA, Risperdal Consta will be marketed in the United States by Janssen Pharmaceutica Products, LP and manufactured by Alkermes. Risperdal is currently the most widely prescribed antipsychotic medication in the United States and would be the first ``atypical'' antipsychotic to be available in a long-acting formulation. Risperdal Consta is a long-acting injectable formulation of Risperdal that uses Alkermes' proprietary, injectable sustained-release drug delivery technology, Medisorb®. The technology is based on the encapsulation of drugs into small polymeric microspheres that degrade slowly and release the medication at a controlled rate following subcutaneous or intramuscular injection. Alkermes is developing Medisorb product candidates in collaboration with pharmaceutical and biotechnology companies and on its own. <snip>